Cargando…

Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats

Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaharyar, Md. Adil, Bhowmik, Rudranil, Afzal, Obaid, Altamimi, Abdulmalik S. A., Alzarea, Sami I., Almalki, Waleed Hassan, Ali, Sk Zeeshan, Mandal, Pallab, Mandal, Avishek, Ayoob, Mohd, Kazmi, Imran, Karmakar, Sanmoy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369749/
https://www.ncbi.nlm.nih.gov/pubmed/35956245
http://dx.doi.org/10.3390/jcm11154628
_version_ 1784766566773030912
author Shaharyar, Md. Adil
Bhowmik, Rudranil
Afzal, Obaid
Altamimi, Abdulmalik S. A.
Alzarea, Sami I.
Almalki, Waleed Hassan
Ali, Sk Zeeshan
Mandal, Pallab
Mandal, Avishek
Ayoob, Mohd
Kazmi, Imran
Karmakar, Sanmoy
author_facet Shaharyar, Md. Adil
Bhowmik, Rudranil
Afzal, Obaid
Altamimi, Abdulmalik S. A.
Alzarea, Sami I.
Almalki, Waleed Hassan
Ali, Sk Zeeshan
Mandal, Pallab
Mandal, Avishek
Ayoob, Mohd
Kazmi, Imran
Karmakar, Sanmoy
author_sort Shaharyar, Md. Adil
collection PubMed
description Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study is to investigate the anti-hypertensive activity of some selected unani formulations using L-NAME model. Method: Group I or hypertensive control group: L-NAME administered for 7 days and left for the next 7 days; Group II or KASgroup: L-NAME administered (i.p) for 7 days and L-NAME + KAS (1000 mg/kg b.w) for the next 7 days; Group III or DMM group: L-NAME administered (i.p) for 7 days and L-NAME + DMM (2000 mg/kg b.w) for the next 7 days; Group IV or MSR group: L-NAME administered (i.p) for 7 days and L-NAME + MSR (300 mg/kg b.w) for the next 7 days; Group V or HJ group: L-NAME administered (i.p) for 7 days and L-NAME + HJ (113 mg/kg b.w) for the next 7 days; Group VI or KGS group: L-NAME administered (i.p) for 7 days and L-NAME +KGS (2000 mg/kg b.w) for the next 7 days. Non-invasive systolic blood pressure and RR-interval (ECG) was measured. Plasma was investigated forsodium, potassium, nitrite, ANP, adrenaline, noradrenaline and aldosterone on day 0, 7 and 14 using LC-MS/MS. Result: Treatment showed a non-significant lowreduction in SBP (systolic blood pressure) of KAS, MSR and HJ while that of DMM was quite significant (p < 0.05), but in the case of KGS, SBP increased. DMM on day 14 significantly (p < 0.05) reduced plasma nitrite while no significant plasma Na+ was noted. In the case of both DMM and KGS, potassium increased significantly (p < 0.05) on day 14. No significant changes in plasma ANP and aldosterone was observed against DMM and KGS while blood levels of adrenaline and noradrenaline significantly (p < 0.05) changed. No significant change in body weight was found. Conclusions: L-NAME KAS, MSR and HJ showed no change in SBP while DMM showed a significant reduction in SBP with decreased plasma nitrite. Probably, DMM may have anti-hypertensive activity mediated through NO inhibition while KGS may involve central sympathomimetic action.
format Online
Article
Text
id pubmed-9369749
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93697492022-08-12 Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats Shaharyar, Md. Adil Bhowmik, Rudranil Afzal, Obaid Altamimi, Abdulmalik S. A. Alzarea, Sami I. Almalki, Waleed Hassan Ali, Sk Zeeshan Mandal, Pallab Mandal, Avishek Ayoob, Mohd Kazmi, Imran Karmakar, Sanmoy J Clin Med Article Background: Systemic arterial hypertension, which is associated with an increased risk of cardiovascular disease(CVD), is the most significant modifiable risk factor for mortality and morbidity worldwide. WHO has recognized Unanipathy as an alternate system of medicine. The aim of the present study is to investigate the anti-hypertensive activity of some selected unani formulations using L-NAME model. Method: Group I or hypertensive control group: L-NAME administered for 7 days and left for the next 7 days; Group II or KASgroup: L-NAME administered (i.p) for 7 days and L-NAME + KAS (1000 mg/kg b.w) for the next 7 days; Group III or DMM group: L-NAME administered (i.p) for 7 days and L-NAME + DMM (2000 mg/kg b.w) for the next 7 days; Group IV or MSR group: L-NAME administered (i.p) for 7 days and L-NAME + MSR (300 mg/kg b.w) for the next 7 days; Group V or HJ group: L-NAME administered (i.p) for 7 days and L-NAME + HJ (113 mg/kg b.w) for the next 7 days; Group VI or KGS group: L-NAME administered (i.p) for 7 days and L-NAME +KGS (2000 mg/kg b.w) for the next 7 days. Non-invasive systolic blood pressure and RR-interval (ECG) was measured. Plasma was investigated forsodium, potassium, nitrite, ANP, adrenaline, noradrenaline and aldosterone on day 0, 7 and 14 using LC-MS/MS. Result: Treatment showed a non-significant lowreduction in SBP (systolic blood pressure) of KAS, MSR and HJ while that of DMM was quite significant (p < 0.05), but in the case of KGS, SBP increased. DMM on day 14 significantly (p < 0.05) reduced plasma nitrite while no significant plasma Na+ was noted. In the case of both DMM and KGS, potassium increased significantly (p < 0.05) on day 14. No significant changes in plasma ANP and aldosterone was observed against DMM and KGS while blood levels of adrenaline and noradrenaline significantly (p < 0.05) changed. No significant change in body weight was found. Conclusions: L-NAME KAS, MSR and HJ showed no change in SBP while DMM showed a significant reduction in SBP with decreased plasma nitrite. Probably, DMM may have anti-hypertensive activity mediated through NO inhibition while KGS may involve central sympathomimetic action. MDPI 2022-08-08 /pmc/articles/PMC9369749/ /pubmed/35956245 http://dx.doi.org/10.3390/jcm11154628 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shaharyar, Md. Adil
Bhowmik, Rudranil
Afzal, Obaid
Altamimi, Abdulmalik S. A.
Alzarea, Sami I.
Almalki, Waleed Hassan
Ali, Sk Zeeshan
Mandal, Pallab
Mandal, Avishek
Ayoob, Mohd
Kazmi, Imran
Karmakar, Sanmoy
Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
title Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
title_full Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
title_fullStr Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
title_full_unstemmed Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
title_short Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats
title_sort anti-hypertensive activity of some selected unani formulations: an evidence-based approach for verification of traditional unani claims using lc-ms/ms for the evaluation of clinically relevant blood parameters in laboratory rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369749/
https://www.ncbi.nlm.nih.gov/pubmed/35956245
http://dx.doi.org/10.3390/jcm11154628
work_keys_str_mv AT shaharyarmdadil antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT bhowmikrudranil antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT afzalobaid antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT altamimiabdulmaliksa antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT alzareasamii antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT almalkiwaleedhassan antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT aliskzeeshan antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT mandalpallab antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT mandalavishek antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT ayoobmohd antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT kazmiimran antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats
AT karmakarsanmoy antihypertensiveactivityofsomeselectedunaniformulationsanevidencebasedapproachforverificationoftraditionalunaniclaimsusinglcmsmsfortheevaluationofclinicallyrelevantbloodparametersinlaboratoryrats